Shares of Metsera, Inc. (NASDAQ:MTSR - Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $15.34 and last traded at $16.45, with a volume of 1606066 shares traded. The stock had previously closed at $16.80.
Wall Street Analyst Weigh In
MTSR has been the subject of several research analyst reports. Cantor Fitzgerald started coverage on Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating for the company. Evercore ISI assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They set an "outperform" rating for the company. Bank of America started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $38.00 target price on the stock. Finally, Guggenheim began coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $56.00 price target for the company.
Get Our Latest Report on MTSR
Metsera Stock Up 7.0 %
The company has a 50 day simple moving average of $25.74.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
